文献速递免疫规划传染病防控与疫情报告

肺炎球菌疫苗接种与鼻咽部定植对血清型特异性尿抗原检测(SSUAD)法性能的影响

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.
PubMed 文献 · Vaccine · 2025-08-30

在一项纳入301名美洲印第安/阿拉斯加原住民的Ⅲ期随机对照试验预设子研究中,评估鼻咽/口咽定植和肺炎球菌疫苗接种对SSUAD检测血清型的影响。结果显示SSUAD阳性率在接种V114/PCV13和PPSV23后短暂升高,且与鼻咽/口咽定植一般无关。作者认为SSUAD可支持肺炎球菌疾病监测和疫苗效果研究,但应排除近期接种肺炎球菌疫苗者以避免假阳性。

要点

  • 在301名美洲印第安/阿拉斯加原住民中,SSUAD检测的血清型阳性率在接种V114/PCV13和PPSV23后短暂升高。
  • SSUAD阳性率一般与鼻咽/口咽肺炎球菌定植无关。
  • 作者建议排除近期接种肺炎球菌疫苗者以避免SSUAD假阳性。

核心结论

  • SSUAD可支持肺炎球菌疾病监测和疫苗效果研究,但应排除近期接种肺炎球菌疫苗的个体以避免假阳性。

研究设计与样本

  • V114-017(NCT03547167;EudraCT 2017-004915-38)是一项Ⅲ期随机对照试验,参与者(18-49岁)接种V114或PCV13,6个月后接种PPSV23。
  • 本报告为嵌套于该Ⅲ期试验的预设子研究,描述性评估鼻咽/口咽定植和肺炎球菌疫苗接种对SSUAD检测血清型的影响。
  • 共301名美洲印第安/阿拉斯加原住民参与子研究,在基线至第7个月(接种PPSV23后30天)之间的10个时间点采集鼻咽/口咽和尿液样本。

主要发现

  • 在任何时间点,10种V114血清型的鼻咽/口咽定植率<2.0%;血清型1的定植率约为2.6%;血清型4、5、9V和33F的定植率在4.0%至7.0%之间。
  • 基线时,SSUAD仅在6名研究参与者中检测到血清型19A、19F和1的肺炎球菌多糖抗原。
  • 接种V114/PCV13和PPSV23后,血清型4、5和9V的SSUAD阳性率短暂升高;接种PPSV23后,血清型19A的SSUAD阳性持续时间最长。
  • SSUAD阳性一般与鼻咽/口咽定植无关。

临床怎么用

  • 作者认为SSUAD可支持肺炎球菌疾病监测和疫苗效果研究,建议排除近期接种肺炎球菌疫苗的个体以避免假阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To better inform pneumococcal immunization policies, ongoing surveillance for pneumococcal community-acquired pneumonia (CAP) is crucial. To estimate the serotype-specific CAP burden of pneumococcal disease following the introduction of a new 15-valent pneumococcal conjugate vaccine (PCV), V114, a 15-plex serotype-specific urine antigen detection (SSUAD) assay was developed as a tool for surveillance of Streptococcuspneumoniae serotypes. V114-017 (NCT03547167; EudraCT 2017-004915-38) was a phase 3 randomized controlled trial in which participants (18-49 years) received V114 or 13-valent PCV (PCV13; as an active comparator), followed 6 months later by 23-valent pneumococcal polysaccharide vaccine (PPSV23). Here, we report findings from a prespecified sub-study nested within the phase 3 trial that descriptively assessed the impact of nasopharyngeal/oropharyngeal (NP/OP) carriage and pneumococcal vaccination on serotype detection with the SSUAD assay. In total, 301 individuals (all American Indian/Alaska Native) participated in the sub-study. NP/OP and urine samples were collected at 10 timepoints between baseline (prior to vaccination) and Month 7 (30 days following vaccination with PPSV23). NP/OP carriage was determined using qualitative polymerase chain reaction for pneumococcus detection and serotyping, and urine samples were tested in parallel with SSUAD. At any timepoint, NP/OP carriage was <2.0 % for 10 of the V114 serotypes; carriage was ∼2.6 % for serotype 1 and ranged between 4.0 % and 7.0 % for serotypes 4, 5, 9V, and 33F. At baseline, serotype-specific pneumococcal polysaccharide antigens were detected by SSUAD in only six study participants for serotypes 19A, 19F, and 1. SSUAD positivity for serotypes 4, 5, and 9V increased transiently following vaccination with V114/PCV13 and PPSV23, while SSUAD positivity lasted the longest for serotype 19A following PPSV23 vaccination. In general, SSUAD positivity appeared unrelated to NP/OP carriage. Our findings suggest SSUAD can support pneumococcal disease surveillance and vaccine effectiveness research, excluding individuals with recent pneumococcal vaccination to avoid false-positives.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cheon K, Buchwald UK, Hammitt LL, et al. The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay. Vaccine. 2025. PMID: 40886427. doi:10.1016/j.vaccine.2025.127453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。